TGFB1 and colorectal carcinoma: The CMS unified earlier expression-based schemes into four reproducible classes with distinct biology and clinical associations, CMS1 (MSI-immune), CMS2 (canonical/WNT-MYC), CMS3 (metabolic/KRAS-enriched), and CMS4 (mesenchymal/TGF-β/angiogenic), and quickly became a popular concept for CRC research and trial design [1].